The forthcoming amendment to the Reimbursement Act is an extensive change, made after ten years of functioning of this legal act in its current form. As emphasized by Michał Byliniak, the challenges faced by the pharmaceutical industry after the changes will be numerous, which is why it was necessary to discuss the amendments by each party. However, such a dialogue was lacking.
– The current shape of the project does not fully reflect our thoughts. We referred to him and for a long time we did not get an answer. We were convinced that there would be more of these consultations, but that did not happen. Last week, another version of the draft was published, signed with a date from a month ago, but it is not known whether it is a version that realistically reflects the arrangements m...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
